Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $34.28 USD
Change Today -0.08 / -0.23%
Volume 13.0M
PFE On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
SIX Swiss Ex
Stockholm
Sao Paulo
Bogota
As of 8:04 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE) Key Developments

Pfizer Eastern Europe Presents at 2015 Russian Pharmaceutical Forum, May-19-2015 06:35 PM

Pfizer Eastern Europe Presents at 2015 Russian Pharmaceutical Forum, May-19-2015 06:35 PM. Venue: Corinthia Hotel, Saint Petersburg, Russia. Speakers: Olga Krylova, Senior Director External R&D Innovation.

Marc Tessier-Lavigne to Step Down from Board of Directors of Pfizer Inc

Pfizer Inc. announced that Director Marc Tessier-Lavigne, Ph.D. has decided to step down from its Board of Directors on May 14, 2015. His decision is coincident with the launch of Denali, a new biotechnology company focused on developing effective therapies for neurodegenerative diseases. Dr. Tessier-Lavigne is a co-founder of Denali, and he will serve as the chairman of the company. Dr. Tessier-Lavigne was appointed to Pfizer’s board of directors in December 2011, and most recently served as a member of the Regulatory and Compliance Committee and Science and Technology Committee.

Pfizer Inc. Announces Executive Changes

Pfizer Inc. announced two strategic appointments in the leadership of the Worldwide Research and Development organization effective immediately. Michael D. Ehlers, M.D., Ph.D., has been selected as Group Senior Vice President and Head of BioTherapeutics Research & Development and Site Head for Cambridge and Boston, Massachusetts locations. Dr. Ehlers will report directly to Mikael Dolsten, M.D., Ph.D., President of Worldwide Research & Development. In addition, John Lin, M.D., Ph.D., has been selected as Senior Vice President and Chief Scientific Officer of Rinat. Dr. Lin will report directly to Robert T. Abraham, Ph.D., Group Senior Vice President for Oncology-Rinat Research & Development. In his expanded role as Head of BioTherapeutics Research & Development, Dr. Ehlers will continue to be Chief Scientific Officer of Pfizer's Neuroscience and Pain Research Unit and he will oversee the entire BioTherapeutics Research & Development organization. In connection with this appointment, the Inflammation and Immunology Research Unit will move to Pfizer's PharmaTherapeutics Research & Development organization. Dr. Ehlers will succeed José-Carlos Gutiérrez-Ramos, Ph.D., who has decided to return to the biotech sector in the Cambridge area.

23andMe, Inc. Launches Lupus Research Study in Collaboration with Pfizer Inc

23andMe, Inc. announced the launch of the Lupus Research Study in collaboration with Pfizer Inc. The companies aim to enroll 5,000 individuals with systemic lupus erythematosus, more commonly known as lupus, into the study to help better understand the genetics of lupus. The effort is also in collaboration with the Lupus Research Institute, and in concert with Lupus Awareness Month in May.

Pfizer Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 through May-05-2015

Pfizer Inc. Presents at NewYork BIO 25th Anniversary Conference 2015, May-04-2015 through May-05-2015. Venue: Time Warner Center, New York, United States. Presentation Date & Speakers: May-04-2015, Sandra Engle, Senior Principal Scientist. May-05-2015, Cyndi Green, Senior Director, Worldwide Business Development.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:US $34.28 USD -0.08

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $111.71 USD +0.49
Merck & Co Inc $59.38 USD -0.72
Nestle SA SFr.73.35 CHF -0.10
Roche Holding AG SFr.278.70 CHF +0.80
Procter & Gamble Co/The $79.95 USD -0.46
View Industry Companies
 

Industry Analysis

PFE

Industry Average

Valuation PFE Industry Range
Price/Earnings 23.8x
Price/Sales 4.3x
Price/Book 3.1x
Price/Cash Flow 16.2x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.